Commercializing CRISPR-Cas9: Regulatory, Ethical and Market Dynamics

Abstract

There are high prospects for making and taking up CRISPR-Cas 9 technology for commercialization in many fields, including health, food, and biologics production. The purpose of this paper is consequently. To investigate and compare the key regulatory, ethical and market drivers of the current CRISPR-based products. The strict rules surrounding regulated industries like healthcare and agriculture are only gradually beginning to extend into the safety and efficacy of Gene-Editing technologies. Still, they also account for closed doors to new and rapidly expanding markets. In ethical consideration, the issues that elicit sensitivity in people and influence policies on regulating the use of genome editing include germline editing and access equity. In competitiveness, market dynamics alter due to competition, sumer pull factors an, and wing trend of applications from CRISPR genomics therapies to genetically modified food crops. It is such accommodative that it is relevant for commercialization of the CRISPR technology given that it continues to experience regulatory, ethical, and market forces that are key to its future growth. Additionally, this paper discusses these dynamics and their validity for the progression of the subsequent phases of CRISPR-Cas9 commercializationis.